title: Incretin-based therapies: facing the realities of benefits versus side effects.
authors.affiliation: State University of New York Health Science Center at Brooklyn , Brooklyn, New York.
authors.forename: Harold E
authors.initials: HE
authors.lastname: Lebovitz
mesh_terms: D000208:Acute Disease; D001786:Blood Glucose / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D003925:Diabetic Angiopathies / Q000517:prevention & control; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D054795:Incretins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced; D010195:Pancreatitis / Q000139:chemically induced* / Q000453:epidemiology; D018027:Receptors, Glucagon / Q000819:agonists* / Q000378:metabolism; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D014839:Vomiting / Q000139:chemically induced
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D054795:Incretins; D018027:Receptors, Glucagon